Details of the Drug

General Information of Drug (ID: DMJV2IF)

Drug Name
JCAR017
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
leukaemia 2A60-2B33 Phase 1/2 [2]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1 [3]
Follicular lymphoma 2A80 Phase 1 [4]
Mantle cell lymphoma 2A85.5 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Primary mediastinal B-cell lymphoma 2A81 Phase 1 [4]
Multiple myeloma 2A83 Clinical trial [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D08BPS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)